Serum chemokine network correlates with chemotherapy in non-small cell lung cancer
Serum chemokine network correlates with chemotherapy in non-small cell lung cancer
复制标题
血清趋化因子网络与非小细胞肺癌化疗相关
DOI：
10.1016/j.canlet.2015.05.001
复制
发表时间：
2015-08-28
期刊：
影响因子：
9.7
通讯作者：
Bai, Chunxue
中科院分区：
文献类型：
--
作者：
Yang, Dawei;Zhou, Jian;Bai, Chunxue
目的：炎症在肺癌微环境中起重要作用。方法：收集非小细胞肺癌（NSCLC）患者50例（腺癌36例，鳞癌14例）和健康非吸烟者14例，采用免疫组化方法检测NSCLC患者血清中炎症标志物网络的表达，并分析其与化疗的关系。健康的患者未接受治疗，而那些患有NSCLC的患者要么是化疗初治，要么接受了一个或两个疗程的化疗。使用多重细胞因子免疫测定法测量细胞因子浓度。采用数字化评分系统（DESS）对临床信息进行评分，以评估患者的严重程度。所有患者完成随访长达2 years.Results：在测量的40个介质中，肺癌患者和健康对照组之间有13个显着差异，而未经治疗的患者和IV期腺癌谁经历了第一和第二个化疗疗程之间有18个不同。多疗程化疗后NSCLC细胞因子的蛋白网络与正常人相似。MIP-3 α是预测NSCLC患者生存率的最重要的生物标志物。结论：我们的数据确定了NSCLC特异性的炎症介质谱，这可能有助于癌症的亚分类，以及治疗效果和总生存率的评估。(C)2015爱思唯尔爱尔兰有限公司版权所有。
Objective: Inflammation plays an important role in the microenvironment of lung cancer. The present study aimed to evaluate the association of inflammatory biomarker networks with chemotherapies for patients with non-small cell lung cancer (NSCLC).Methods: The sera of healthy non-smokers (n = 14) and patients with NSCLC (n = 50), 36 with adenocarcinoma and 14 with squamous cell carcinoma, were collected. Healthy patients were untreated, while those with NSCLC were either chemotherapy-na ve or had received one and two courses of chemotherapy. The cytokine concentrations were measured using multiplexed cytokine immunoassays. The clinical informatics was scored with a Digital Evaluation Score System (DESS) to assess the severity of the patients. All patients completed follow-up for up to 2 years.Results: Among the 40 mediators measured, 13 significantly differed between patients with lung cancer and healthy controls, while 18 differed between untreated patients and those with stage IV adenocarcinoma who had undergone the first and second chemotherapy courses. The protein network of cytokines in NSCLC after multiple courses of chemotherapy was similar to that of normal persons. MIP-3 alpha is the most crucial biomarker for predicting survival rates in NSCLC patients.Conclusions: Our data identify an NSCLC-specific profile of inflammatory mediators that may be useful for cancer sub-classification, as well as the evaluation of therapeutic effects and overall survival. (C) 2015 Elsevier Ireland Ltd. All rights reserved.